Tuesday 9th May at 6:00pm – “PRRT- One year on”.

We are delighted to welcome Dr Chander as a guest speaker for our WebiNatter on Tuesday 9th May. Dr. Amarjot Chander is a Consultant Radiologist and Nuclear Medicine Physician at The Christie NHS Foundation Trust in Manchester – with responsibility for the delivery and service development of the PET-CT, PRRT, and SIRT services.

Her specialties include diagnostic and radionuclide radiology including PET CT. Her subspecialty interest is in radionuclide therapy. Therapy specialties are Selective Internal Radiation Therapy (SIRT) and Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumours.

If you have any questions you would like to ask – you can pre-submit them by email to Nikie: to be received by 5:00pm on Sunday 7th May.

You will have the opportunity to ask questions after Dr. Chander’s talk in our Q&A session: but please note that Dr. Chander cannot comment on your personal care.

 

To join this Webi-Natter – please self-register HERE.

 

Peptide Receptor Radionuclide Therapy (PRRT) is a type of targeted cancer treatment that uses a small amount of radioactive material to kill cancer cells. It is mostly used to treat neuroendocrine tumours (NETs) that have spread to other parts of the body. The therapy works by attaching a radioactive material to a molecule called a peptide that targets and binds to receptors on the surface of cancer cells. Once the radioactive material is attached to the cancer cells, it emits radiation that damages the DNA of the cancer cells, eventually killing them. PRRT is usually given by injection and is often used in combination with other treatments like surgery or chemotherapy.